Company news
Rallybio Corporation news in 2024
Rallybio Corporation's news releases, calls and decks from 2024, newest first.
Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting
December 9, 2024
Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025
December 1, 2024
Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women
November 26, 2024
Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor
November 24, 2024
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212
November 20, 2024
Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 6, 2024
Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT
October 28, 2024
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting
September 22, 2024
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit
September 9, 2024
Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree
September 8, 2024
Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis
August 28, 2024
Rallybio to Present at Upcoming Investor Conferences
August 26, 2024
Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 7, 2024
Rallybio to Present at the 2024 Jones Healthcare Seaside Summit
July 8, 2024
Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations
June 16, 2024
Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates
May 8, 2024
Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference
May 6, 2024
FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting
April 16, 2024
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
April 9, 2024
Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting
March 31, 2024
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results
March 11, 2024
Rallybio to Present at the TD Cowen 44th Annual Health Care Conference
February 25, 2024
Rallybio Announces Portfolio Prioritization and Provides Corporate Update
February 5, 2024
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024
January 3, 2024